Intriguingly, tamibarotene showed better tumor reduction and more prolonged survival than ATRA, indicating that tamibarotene has higher potency against RARα-high AML cells, consistent with previous clinical studies showing the superiority of tamibarotene over ATRA in APL [47]. This evidence concerns the gene RARA and acute myeloid leukemia.